Table 2.
Comorbidities, COVID-19 infection, and vaccination status of PWE during the first month after vaccination.
| Increase >50% seizure frequency during the first month after vaccination | No increase in seizure frequency during the first month after vaccination | p | ||
|---|---|---|---|---|
| (n = 26) | (n = 392) | |||
| Comorbidities | Hypertension | 8 (30.8%) | 88 (22.4%) | 0.329 |
| Diabetes mellitus | 3 (11.5%) | 26 (6.6%) | 0.411 | |
| Dyslipidemia | 6 (23.1%) | 78 (19.9%) | 0.695 | |
| Neoplastic disease | 4 (15.4%) | 47 (12.0%) | 0.542 | |
| Pneumological disease | 5 (19.2%) | 52 (13.3%) | 0.391 | |
| Neurological disease (different from epilepsy) | 9 (34.6%) | 141 (36.0%) | 0.889 | |
| Cardiological disease | 4 (15.4%) | 46 (11.7%) | 0.539 | |
| Immunosuppression | 2 (7.7%) | 17 (4.3%) | 0.334 | |
| History of positive test for SARS-CoV-2 | 3 (11.5%) | 75 (19.2%) | 0.441 | |
| Vaccine type | Pfizer | 16 (61.5%) | 255 (65.1%) | 0.973 |
| AZ | 1 (3.8%) | 10 (2.5%) | ||
| Moderna | 3 (11.5%) | 45 (11.5%) | ||
| Jansen | 0 | 3 (0.8%) | ||
| Heterologous | 6 (23.1%) | 79 (20.1%) | ||
| Total number of doses received | 1 dose | 1 (3.8%) | 23 (5.9%) | 0.945 |
| 2 doses | 14 (53.8%) | 219 (55.9%) | ||
| (including Jansen’s 2nd dose- booster) | ||||
| 3 doses | 11 (42.4%) | 150 (38.2%) | ||
AZ: AstraZeneca. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.